Browse RMM Directory A-Z

${pdf_link}$

Padcev Patient Card

Every Padcev pack contains a Patient Card. The purpose of the patient card is to provide: - Information for patients that Padcev treatment may cause severe skin reactions - Description of symptoms of the safety concern and when to seek medical care - Information for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is being treated with Padcev which can cause severe skin reactions - Contact details of the treating physician who has prescribed Padcev Patients should carry the Patient Card at all times and present it to any healthcare professional they might interact with.

${pdf_link}$

Pamidronate Patient Reminder Card

contains important safety information that patients need to be aware of before and during treatment with pamidronate disodium injections

${pdf_link}$

Pamidronate Patient Reminder Card Cover Letter

is a letter which should be viewable only by the HCP. It details the requirement for the dispensing pharmacist to discuss the contents of the Patient Reminder Card with the patient prior to dispensing.

${pdf_link}$

PecFent - UK Patient and Carer guide

Patient/carer’s guide to PecFent® (fentanyl citrate) nasal spray

${pdf_link}$

PecFent - UK Pharmacists Brochure

Pharmacist’s guide to dispensing PecFent® (fentanyl citrate) nasal spray

${pdf_link}$

PecFent - UK Prescribers Brochure

Physician’s guide to prescribing PecFent® (fentanyl citrate) nasal spray

${pdf_link}$

Penthrox Administration Checklist-HCP use

'Checklist to aid HCPs in the selection of appropriate patients for treatment with Penthrox’ Further copies of the educational materials and training on the administration of Penthrox are available from Galen on request (tel 028 38334974 or email [email protected]).

${pdf_link}$

Penthrox Administration Guide-HCP use

Penthrox Administration Guide-HCP use Further copies of the educational materials and training on the administration of Penthrox are available from Galen on request (tel 028 38334974 or email [email protected]).

${pdf_link}$

Penthrox Patient Alert Card-Patient Use

${pdf_link}$

Peyona (caffeine citrate) 20 mg/ml Solution for Infusion and Oral Solution Laminated Card

Before using Peyona (caffeine citrate) 20 mg/ml either intravenously or orally, in addition to reading the Summary of Product Characteristics, please check the following points:

${pdf_link}$

Peyona (caffeine citrate) 20mg/ml solution for infusion and oral solution

Information on the safe use of Peyona (caffeine citrate) 20mg/ml solution for infusion and oral solution

${pdf_link}$

Piasky ®▼(crovalimab) Healthcare Professional Guide

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

${pdf_link}$

Piasky ®▼(crovalimab) Patient Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Piasky ®▼(crovalimab) Patient caregiver guide

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

${pdf_link}$

Piqray-Educational material - Guide for healthcare professionals - Management of risk of hyperglycaemia - digital version

The objective of these materials is to raise awareness of the increased risk of hyperglycaemia associated with alpelisib treatment, as well as to provide information concerning: - signs and symptoms of severe hyperglycaemia (including ketoacidosis) - monitoring required before and during treatment - management of hyperglycaemia associated with alpelisib

${pdf_link}$

SAFETY CHECKLIST FOR PRESCRIBING PHYSICIAN

${pdf_link}$

Safety Checklist for Prescribing Physician

The safety checklist contains important key elements on photosensitivity and drug-induced liver injury that are to follow during treament with pirfenidone.

${pdf_link}$

Pirfenidone Safety Checklist for Prescribers

Safety checklist contains key elements to follow when prescribing Pirfenidone Film-coated Tablets

${pdf_link}$

Pirfenidone Safety Checklist for Prescribing Physicians

Safety checklist contains key elements to follow when prescribing Pirfenidone Film-Coated Tablets

${pdf_link}$

Pirfenidone Safety Checklist for Prescribing Physician

The safety checklist contains key elements to follow when prescribing Pirfenidone

${pdf_link}$

Pirfenidone Safety Checklist

SAFETY CHECKLIST FOR PRESCRIBING PHYSICIAN

${pdf_link}$

SAFETY CHECKLIST FOR PRESCRIBING

This safety checklist contains key elements to follow when prescribing Pirfenidone Film-Coated Tablets

${pdf_link}$

Safety Checklist for Prescribing Physician

This safety checklist contains key elements to follow when prescribing Pirfenidone

${pdf_link}$

Pirfenidone 267mg and 801mg safety checklist for prescribing physician

This educational material is provided to alert the prescribing physician of Drug-induced liver injury (DILI) and Photosensitivity reactions and rash associated with the use of pirfenidone and to guide healthcare professionals in managing these risks with their patients.

${pdf_link}$

Pirfenidone Prescriber's Checklist

Prescriber's checklist for Teva's Pirfenidone 267mg and 801mg Film-Coated Tablets.

${pdf_link}$

Pomalidomide Adverse Event report form

${pdf_link}$

Pomalidomide HCP Information Guide

${pdf_link}$

Pomalidomide Male Risk Awareness form

${pdf_link}$

Pomalidomide offline PAF

Prescription Authorisation Form

${pdf_link}$

Pomalidomide Patient Card

Pomalidomide Patient card

${pdf_link}$

Pomalidomide Patient Information Guide

${pdf_link}$

Pomalidomide Pharmacy Registration Form

${pdf_link}$

Pomalidomide Pregnancy outcome form

${pdf_link}$

Pomalidomide Pregnancy report form

${pdf_link}$

Pomalidomide Risk Assessment form - WCBP

Pomalidomide Risk Assessment form - Woman of Childbearing Potential

${pdf_link}$

Pomalidomide Risk Assessment form - WNCBP

Pomalidomide Risk Assessment form - Woman of non Childbearing Potential

${pdf_link}$

CIPAGLUCOSIDASE ALFA HOME INFUSION PATIENT DIARY

HOME INFUSION PATIENT DIARY

${pdf_link}$

CIPAGLUCOSIDASE ALFA HOME INFUSION PATIENT MANUAL

HOME INFUSION PATIENT MANUAL

${pdf_link}$

Patient Reminder Card for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for women of childbearing potential

Patient reminder card

${pdf_link}$

POMBILITI (CIPAGLUCOSIDASE ALFA) + OPFOLDA (MIGLUSTAT) INFORMATION PACK FOR HEALTHCARE PROFESSIONALS

INFORMATION PACK FOR HEALTHCARE PROFESSIONALS

${pdf_link}$

Checklist for the Prescriber

${pdf_link}$

Specific Patient Information

${pdf_link}$

Pradaxa (dabigatran etexilate) coated granules Patient Alert Card

Every patient prescribed Pradaxa in the medication package will receive a Patient Alert Card. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.

${pdf_link}$

Pradaxa (dabigatran etexilate) Patient Alert Card

Every patient prescribed Pradaxa will receive a Patient Alert Card in the medication pack. As the card contains important information the patient should be instructed to carry the patient alert card at all times and present it when seeing a health care professional. The patient should be counselled about the need for compliance and signs of bleeding and when to seek medical attention.

${pdf_link}$

Pradaxa (dabigatran etexilate) Prescriber guide for paediatric use for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from the time the child is able to swallow food to less than 18 years of age

This risk minimisation material provides recommendations for the use of Pradaxa for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from the time the child is able to swallow food to less than 18 years of age (paed. VTE) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa in the paediatric population and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

${pdf_link}$

Pradaxa (dabigatran etexilate) Prescriber guide for primary prevention of venous thromboembolic events (VTE) following elective hip or knee replacement surgery

This risk minimisation material provides recommendations for the use of Pradaxa in VTE (orthopaedic) in order to minimise the risk of bleeding. Please ensure you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

${pdf_link}$

Pradaxa (dabigatran etexilate) Prescriber Guide for stroke prevention in non-valvular atrial fibrillation (NVAF) and for the treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

This risk minimisation material provides recommendations for the use of Pradaxa in NVAF and DVT/PE in order to minimise the risk of bleeding. Please ensure that you are familiar with this material as it contains important safety information. In particular it is aimed at increasing awareness about the potential risk of bleeding during treatment with Pradaxa and providing guidance on how to manage that risk. For hard copies please contact our medical information department at 01344 424600 or email: [email protected]

${pdf_link}$

Prasugrel Educational material for Healthcare Professional

Educational material for Healthcare Professional regarding Prasugrel 5 mg and 10 mg film-coated tablets

${pdf_link}$

Educational-material-Prasugrel Waymade 5mg and 10 mg film-coated tablets

This is an educational material for Prasugrel 5mg and 10mg fim-coated tablets

${pdf_link}$

Prasugrel

EDUCATIONAL MATERIAL FOR HEALTH CARE PROFESSIONALS:

Educational material for all physicians who may be involved in treating patients with

prasugrel, specifically to minimise the bleeding risk in patients ≥75 years of age and

patients weighing < 60kg

${pdf_link}$

Prenoxad® Injection Client's Guide

This booklet is for anyone who has been supplied with Prenoxad® Injection

${pdf_link}$

Prenoxad® Injection Issuer’s Guide

Please review this document carefully before issuing Prenoxad® Injection.

${pdf_link}$

Prenoxad® Injection Training Checklist

This Training Checklist can be used to help with delivery of ‘refresher’ training, and when making first or replacement supplies of Prenoxad Injection.

${pdf_link}$

Prenoxad® Injection Training Manual

Prenoxad Injection Training Manual

${pdf_link}$

PROCYSBI - AE Follow Up Form for Fibrosing Colonopathy

Pharmacovigilance follow up form for suspected ADR after PROCYSBI - questionnaire for detailed follow-up of possible signs suggestive of fibrosing colonopathy

${pdf_link}$

PROCYSBI - AE Follow Up Form for Pregnancy

Pharmacovigilance follow up form for pregnancy after PROCYSBI

${pdf_link}$

Procysbi - Safety Checklist for Prescribing Physicians

The Safety Checklist is intended to ensure the safe and effective use of Procysbi. It addresses specifically the following potential risks associated with the use of this product: Fibrosing colonopathy, teratogenicity.

${pdf_link}$

Produodopa Patient Guide

Patient guide essential to ensure the safe and effective use of the product and provides guidance on preventing and managing the risk of infusion site side effects (infection and reaction).

${pdf_link}$

Pro-Epanutin in Status Epilepticus. Dosing Aid For Adults Only

This dosing aid is designed to help you administer a loading dose of fosphenytoin. Use the equations and/or consult the dosing table to determine the appropriate dosing information based on patient weight.

${pdf_link}$

Pro-Epanutin in Status Epilepticus. Dosing Aid For Children 5 years and older

For Children 5 years and older. This dosing aid is designed to help you administer a loading dose of fosphenytoin. Use the equations and/or consult the dosing table to determine the appropriate dosing information based on patient weight.

${pdf_link}$

Prolia patient reminder card

This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (Prolia), which is used to treat osteoporosis and bone loss. A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely (may affect up to 1 in 1,000 people) in patients receiving Prolia for osteoporosis. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions patients should take. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

${pdf_link}$

Rivastigmine patch (Exelon/Prometax) - Instructions for use and patient diary - for patients

Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Exelon Patch or Prometax Patch (rivastigmine transdermal system) to ensure the correct use of the patch.

Risk Minimisation Materials

Padcev

Astellas Pharma Ltd

Pamidronate Disodium

Hospira UK Ltd

PecFent

Grunenthal Meds

Penthrox

Galen Limited

Peyona

Chiesi Limited

Piasky

Roche Products Limited

Piqray

Novartis Pharmaceuticals UK Ltd

Pirfenidone

Amarox Limited

axunio Pharma GmbH

Celix Pharma Ltd

Dr. Reddy's Laboratories (UK) Ltd

Glenmark Pharmaceuticals Europe Ltd

Laboratorios Liconsa, S.A.

Lupin Healthcare (UK) Ltd

MSN Laboratories Europe Ltd

Sandoz Limited

Teva UK Limited

Pomalidomide

Zentiva

Pombiliti

Amicus Therapeutics UK Ltd

Powergel

A. Menarini Farmaceutica Internazionale SRL

Pradaxa

Boehringer Ingelheim Limited

Prasugrel

MSN Laboratories Europe Ltd

Sovereign Medical

Strandhaven Limited t/a Somex Pharma

Prenoxad

Martindale Pharma, an Ethypharm Group Company

Procysbi

Chiesi Limited

Produodopa

AbbVie Ltd

Pro-Epanutin

Pfizer Limited

Prolia

Amgen Ltd

Prometax

Novartis Pharmaceuticals UK Ltd

You are trying to reach document intended for healthcare professionals only.